BioAlliance Pharma announces that the civil action filed by Eurofins in the United States is rejected

BioAlliance Pharma SA (Euronext Paris – BIO) announces today that the American District Judge has granted the motion to dismiss of BioAlliance Pharma and one of its executive in response to the civil action filed by Eurofins. Eurofins filed an appeal.
In 2008, Eurofins Pharma US Holding Inc. and one of its affiliates Viralliance Inc (“Eurofins”) had filed a civil action against BioAlliance (Press release of BioAlliance 14 October 2008). This US action concerned the diagnostic technology (Phenoscript® test of HIV drug resistance) transferred by BioAlliance Pharma to Eurofins.
Furthermore, BioAlliance Pharma instituted legal proceedings against Eurofins in Paris in January 2009 for non-development of the technology and harm of its image.
BioAlliance was advised by Ron Soffer, Attorney at Law, Member of the Paris Bar.

0909122EN_Eurofins US